SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Venture Capital
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kevin Thompson who wrote ()6/9/1998 6:50:00 AM
From: Stephen Goldfarb  Read Replies (1) of 26
 
A biotechnology company of which I am aware (I am a shareholder) has a need for funds. The company has a treatment for auto-immune diseases. They have successfully tested their treatment on diseases such as rheumatoid arthritis and other auto-immune diseases (including Aids). Some reports indicate dramatic improvement. Patients reportedly have remained in remission for extended periods.

The head scientist is internationally known and published. The company has been in existence for over 10 years. The company's personnel have been working without salary in furtherance of their science.

The core problem is the need to convert the polyclonal human protein antibodies that are used in the treatment to monoclonal. This is to avoid rejection from repeat use. To convert to monoclonal is expensive. The company will then need to engage in Phase II testing to get FDA approval.

I have heard various figures, but believe they will require in the neighborhood of $5 million. I would like to help them find capital. Hopefully, an angel will, upon investigation, wish to support their scientific effort. A business plan is available. The market for a treatment for rheumatoid arthritis is, by itself, enormous. I can put any interested party in touch with the company. I am interested in direct interest, comment, or direction.

Stephen Goldfarb
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News